Spyre Therapeutics, Inc.
SYRE$2.57B
Mid CapNASDAQBiotechnology🇺🇸North America95 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Jun 15, 2026
13wMarket Overview
Stock performance and key metrics
SYRE News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SPY002-072 | Phase 2 | Rheumatoid Arthritis | - | - |
SPY001 | Phase 2 | Ulcerative Colitis | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply